Parkinson Disease

• CLINICAL_TRIALS withdrawal · 2020-06-17
  Clinical Trial Update: Safinamide for Levodopa-induced Dyskinesia (PD-LID) [Phase 3]

  Phase 3 clinical trial for safinamide in Parkinson disease with levodopa-induced dyskinesia has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2019-12-10
  Clinical Trial Update: A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations [Phase 3]

  A Phase 3 trial evaluating ND0612 infusion as an adjunct to levodopa in Parkinson's disease has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2019-02-04
  Clinical Trial Update: Post Market (Brio™ System) Deep Brain Stimulation (DBS) PD Study

  A post-market study evaluating Abbott's Brio deep brain stimulation system for Parkinson's disease has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2018-11-23
  Clinical Trial Update: A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension [Phase 3]

  A Phase 3 study evaluating relative bioavailability of ND0612 subcutaneous levodopa versus enteral carbidopa-levodopa has been withdrawn.

• EMA withdrawal · 2018-08-09
  EMA Withdrawn: Numient (levodopa;carbidopa) — Amneal Pharma Europe Ltd

  Numient (levodopa; carbidopa) has been withdrawn from the European market by Amneal Pharma Europe Ltd for Parkinson's disease.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA withdrawal · 2018-07-11
  EMA Application withdrawn: Rotigotine Mylan (rotigotine) — Mylan S.A.S

  The EMA has withdrawn the marketing authorization application for Rotigotine Mylan (rotigotine) submitted by Mylan S.A.S, for restless legs …

• CLINICAL_TRIALS withdrawal · 2018-03-26
  Clinical Trial Update: The Safety of Remote DBS Programming System [NA]

  The clinical trial evaluating the safety of a remote deep brain stimulation programming system for Parkinson's disease has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2018-03-22
  Clinical Trial Update: Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED) [Phase 2]

  A Phase 2 study evaluating Foliglurax (PXT002331) for reducing levodopa-induced dyskinesia and wearing-off in Parkinson's disease has been w…

• CLINICAL_TRIALS withdrawal · 2017-12-12
  Clinical Trial Update: A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients [Phase 2]

  A Phase 2 trial evaluating a multidisciplinary approach to manage gait difficulty in Parkinson's disease was withdrawn.

• CLINICAL_TRIALS withdrawal · 2017-11-24
  Clinical Trial Update: Study to Assess the Safety and Effects of Autologous Adipose-Derived SVF Cells in Patients With Parkinson's Disease [NA]

  The study evaluating autologous adipose-derived stromal vascular fraction (SVF) cells for Parkinson's disease has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2017-10-06
  Clinical Trial Update: Convection-Enhanced Delivery to Study the Pathophysiology Underlying the Clinical Features of Parkinson s Disease [Phase 1]

  A Phase 1 trial investigating convection-enhanced delivery to study the pathophysiology underlying Parkinson's disease has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2017-09-13
  Clinical Trial Update: A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes [Phase 3]

  Phase 3 trial evaluating [123I]NAV5001 for imaging Parkinsonian syndromes was withdrawn.

• CLINICAL_TRIALS withdrawal · 2017-04-27
  Clinical Trial Update: Hub and Spoke, Comparative Outcomes for Parkinson's Disease Treated With Deep Brain Stimulation [NA]

  The clinical trial NCT02541617 investigating hub-and-spoke deep brain stimulation for Parkinson's disease has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2017-02-23
  Clinical Trial Update: Piloting a Novel, Mobile Cognitive Tracking and Training Tool for Patients With Parkinson's Disease (PD) [NA]

  A clinical trial investigating a novel mobile cognitive tracking and training tool for Parkinson's disease has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2017-02-07
  Clinical Trial Update: Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) [Phase 2]

  A Phase 2 trial of incobotulinum toxin A for sialorrhea in Parkinson disease and amyotrophic lateral sclerosis has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2016-11-17
  Clinical Trial Update: Concurrent DBS Local Field Potential Analysis and Stimulation in a Closed-Loop Neuromodulation Device [NA]

  The clinical trial evaluating concurrent deep brain stimulation with local field potential analysis for a closed-loop neuromodulation device…

• CLINICAL_TRIALS withdrawal · 2016-08-05
  Clinical Trial Update: Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients [Phase 1]

  A Phase 1 study evaluating AFFITOPE PD01A in Parkinson's disease patients with GBA mutations was withdrawn.

• CLINICAL_TRIALS withdrawal · 2016-04-06
  Clinical Trial Update: Natural History of Levodopa-Induced Dyskinesia (LID)

  The clinical trial studying the natural history of levodopa-induced dyskinesia in Parkinson's disease has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2016-02-25
  Clinical Trial Update: Characterizing the Specificity and Stability of Local Field Potentials in the Globus Pallidus Internus of Patients Undergoing Deep Brain Stimulation for Parkinson's Disease [Phase 1]

  Phase 1 clinical trial evaluating the specificity and stability of local field potentials in the globus pallidus internus during deep brain …

• CLINICAL_TRIALS withdrawal · 2015-11-24
  Clinical Trial Update: Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension Study [Phase 2]

  Phase 2 open-label safety extension trial of a gastric-retentive formulation of carbidopa/levodopa for Parkinson's disease has been withdraw…

• CLINICAL_TRIALS withdrawal · 2015-11-13
  Clinical Trial Update: Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease [NA]

  The clinical trial evaluating acamprosate for compulsive behaviors and craving in Parkinson's disease has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2015-09-16
  Clinical Trial Update: Parkinson's Disease Genetics Database

  A Northwell Health–sponsored clinical trial investigating a Parkinson's Disease genetics database was terminated.

• CLINICAL_TRIALS withdrawal · 2015-06-26
  Clinical Trial Update: Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease [NA]

  A clinical trial comparing modafinil and methylphenidate for excessive daytime sleepiness in Parkinson's disease was withdrawn.

• CLINICAL_TRIALS withdrawal · 2015-05-15
  Clinical Trial Update: Nurse Management of Neuromodulation Therapy [NA]

  The clinical trial evaluating nurse management of neuromodulation therapy for Parkinson's disease has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2015-03-10
  Clinical Trial Update: Cellular Proteome From Leukocytes of Glaucoma Patients in Comparison With Patients With Parkinson's Disease

  The clinical trial evaluating the cellular proteome from leukocytes in glaucoma patients and in patients with Parkinson's disease has been w…